JO3648B1 - عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا - Google Patents
عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائياInfo
- Publication number
- JO3648B1 JO3648B1 JOP/2015/0184A JOP20150184A JO3648B1 JO 3648 B1 JO3648 B1 JO 3648B1 JO P20150184 A JOP20150184 A JO P20150184A JO 3648 B1 JO3648 B1 JO 3648B1
- Authority
- JO
- Jordan
- Prior art keywords
- naphthyridine
- methoxyphenyl
- dihydro
- ethoxy
- cyano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179544 | 2014-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3648B1 true JO3648B1 (ar) | 2020-08-27 |
Family
ID=51260727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2015/0184A JO3648B1 (ar) | 2014-08-01 | 2015-07-30 | عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | USRE49575E1 (enExample) |
| EP (2) | EP3660015A1 (enExample) |
| JP (1) | JP6818674B2 (enExample) |
| KR (3) | KR102830206B1 (enExample) |
| CN (4) | CN106795155B (enExample) |
| AR (1) | AR101403A1 (enExample) |
| AU (1) | AU2015295376C1 (enExample) |
| BR (1) | BR112017001678B1 (enExample) |
| CA (2) | CA2956529A1 (enExample) |
| CL (1) | CL2017000263A1 (enExample) |
| CO (1) | CO2017000886A2 (enExample) |
| DK (1) | DK3174875T3 (enExample) |
| ES (1) | ES2828704T3 (enExample) |
| HR (1) | HRP20201800T1 (enExample) |
| HU (1) | HUE051350T2 (enExample) |
| IL (1) | IL250239B (enExample) |
| JO (1) | JO3648B1 (enExample) |
| LT (1) | LT3174875T (enExample) |
| MX (1) | MX369467B (enExample) |
| MY (1) | MY198066A (enExample) |
| PE (1) | PE20170141A1 (enExample) |
| PL (1) | PL3174875T3 (enExample) |
| PT (1) | PT3174875T (enExample) |
| RS (1) | RS60921B1 (enExample) |
| RU (1) | RU2729998C9 (enExample) |
| SG (1) | SG11201700785UA (enExample) |
| SI (1) | SI3174875T1 (enExample) |
| TW (1) | TWI684593B (enExample) |
| UA (1) | UA122773C2 (enExample) |
| UY (1) | UY36251A (enExample) |
| WO (1) | WO2016016287A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA122773C2 (uk) * | 2014-08-01 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | Спосіб одержання (4s)-4-(4-ціано-2-метоксифеніл)-5-етокси-2,8-диметил-1,4-дигідро-1,6-нафтиридин-3-карбоксаміду і його очищення для застосування як фармацевтичного активного інгредієнта |
| PT3337800T (pt) * | 2015-08-21 | 2019-08-05 | Bayer Pharma AG | Método para a preparação de (4s)-4-(4-ciano-2-metoxi fenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1-6-naftiridina-3- carboxamida e purificação do mesmo para a utilização como ingrediente farmacêutico ativo |
| EP3560922A1 (de) | 2018-04-24 | 2019-10-30 | Bayer Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester |
| CA3132399A1 (en) | 2019-03-05 | 2020-09-10 | Bayer Aktiengesellschaft | Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine |
| JP2022523984A (ja) | 2019-03-05 | 2022-04-27 | バイエル アクチェンゲゼルシャフト | ４－アミノ－５－メチルピリドンを調製する方法 |
| CR20220159A (es) * | 2019-10-17 | 2022-06-02 | Bayer Ag | Procedimiento para la preparación de (4s)–4–(4–ciano–2–metoxi–fenil)–5–hidroxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo por separación de racematos por medio de éster de ácido tartárico diastereoisómero |
| EP4045501A1 (de) * | 2019-10-17 | 2022-08-24 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester |
| MX2022004480A (es) * | 2019-10-17 | 2022-05-06 | Bayer Ag | Procedimiento para preparar esteres aciloximetilicos del acido (4s)-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6- naftiridin-3-carboxilico. |
| AU2020365351A1 (en) | 2019-10-17 | 2022-05-12 | Bayer Aktiengesellschaft | Photochemical process for producing (4R,4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamide |
| EP4138826A1 (en) | 2020-04-22 | 2023-03-01 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| EP3900722A1 (en) | 2020-04-22 | 2021-10-27 | Bayer AG | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
| WO2021254896A1 (en) | 2020-06-16 | 2021-12-23 | Bayer Aktiengesellschaft | Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction |
| CN112237573B (zh) * | 2020-10-29 | 2023-12-22 | 瑞阳制药股份有限公司 | 含finerenone的片剂及其制备方法 |
| WO2022214206A1 (en) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
| CN114149427A (zh) * | 2021-12-18 | 2022-03-08 | 上海鼎雅药物化学科技有限公司 | 非奈利酮及其中间体的合成方法 |
| CN115340539B (zh) | 2022-01-19 | 2024-02-27 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
| CN115340540A (zh) * | 2022-01-20 | 2022-11-15 | 奥锐特药业股份有限公司 | 制备非奈利酮及其中间体的方法 |
| CN114524812A (zh) * | 2022-03-18 | 2022-05-24 | 湖南凯铂生物药业有限公司 | 1,4-二氢-1,6-萘啶化合物的晶型制备以及合成方法 |
| EP4511365A1 (en) | 2022-04-18 | 2025-02-26 | Teva Pharmaceuticals International GmbH | Processes for the preparation of finerenone |
| EP4286368A1 (de) | 2022-05-31 | 2023-12-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril |
| WO2024075139A1 (en) * | 2022-10-06 | 2024-04-11 | Maithri Drugs Private Limited | A process for preparation of finerenone and intermediates thereof |
| JP2025537211A (ja) | 2022-11-04 | 2025-11-14 | ナンジン ブイケア ファーマテック カンパニー リミテッド | ジアステレオマー酒石酸エステルによりラセミ体を分割することによりフィネレノンを調製する方法 |
| AU2023385074A1 (en) * | 2022-11-23 | 2025-05-15 | Bayer Aktiengesellschaft | Treatment of chronic kidney disease in type i diabetes mellitus |
| IL321272A (en) | 2022-12-16 | 2025-08-01 | Bayer Ag | Continuous one-pot synthesis for the preparation of 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxamide |
| WO2024147053A1 (en) * | 2023-01-03 | 2024-07-11 | Optimus Drugs Pvt Ltd | Improved process for the preparation of finerenone |
| TW202438065A (zh) * | 2023-03-17 | 2024-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 1,4-二氫-1,6-萘啶醯胺化合物的可藥用鹽、晶型及其製備方法 |
| WO2025104752A1 (en) * | 2023-11-18 | 2025-05-22 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of (4s)4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
| CN120081840A (zh) * | 2023-12-01 | 2025-06-03 | 山东诚创蓝海医药科技有限公司 | 一种非奈利酮-马来酸共晶及其制备方法 |
| US20250313559A1 (en) | 2024-01-05 | 2025-10-09 | Bayer Aktiengesellschaft | Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
| WO2025247801A1 (en) * | 2024-05-30 | 2025-12-04 | Bayer Aktiengesellschaft | Determination of a dosage of a nonsteroidal mineralocorticoid receptor antagonist |
| CN119462643A (zh) * | 2024-10-17 | 2025-02-18 | 河北国龙制药有限公司 | 一种非奈利酮单晶及其制备方法和应用 |
| CN119019395A (zh) * | 2024-10-29 | 2024-11-26 | 成都诺和晟欣生物医药有限公司 | 一种非奈利酮晶型ⅰ的制备方法 |
| CN119684288A (zh) * | 2024-12-18 | 2025-03-25 | 安徽先和医药研究有限公司 | 非奈利酮的制备方法 |
| CN119684289A (zh) * | 2024-12-18 | 2025-03-25 | 安徽先和医药研究有限公司 | 一种非奈利酮的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL75987A (en) * | 1984-08-25 | 1991-07-18 | Goedecke Ag | Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them |
| US4895860A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corporation | Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9914825D0 (en) | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2006044775A2 (en) * | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| AU2005311930B9 (en) * | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
| AU2006201739A1 (en) * | 2005-05-05 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles |
| US20080312209A1 (en) | 2005-07-12 | 2008-12-18 | Glaxo Group Limited | Piperazine Heteroaryl Derivatives as Gpr38 Agonists |
| DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
| DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
| DE102007009494A1 (de) * | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| CN102020587A (zh) | 2010-11-25 | 2011-04-20 | 大连凯飞精细化工有限公司 | 2-甲氧基-4-氰基苯甲醛的合成方法 |
| UA122773C2 (uk) * | 2014-08-01 | 2021-01-06 | Байєр Фарма Акцієнгезелльшафт | Спосіб одержання (4s)-4-(4-ціано-2-метоксифеніл)-5-етокси-2,8-диметил-1,4-дигідро-1,6-нафтиридин-3-карбоксаміду і його очищення для застосування як фармацевтичного активного інгредієнта |
-
2015
- 2015-07-29 UA UAA201701875A patent/UA122773C2/uk unknown
- 2015-07-29 WO PCT/EP2015/067340 patent/WO2016016287A1/de not_active Ceased
- 2015-07-29 AU AU2015295376A patent/AU2015295376C1/en active Active
- 2015-07-29 DK DK15742306.2T patent/DK3174875T3/da active
- 2015-07-29 KR KR1020237014295A patent/KR102830206B1/ko active Active
- 2015-07-29 CN CN201580053456.7A patent/CN106795155B/zh active Active
- 2015-07-29 HU HUE15742306A patent/HUE051350T2/hu unknown
- 2015-07-29 ES ES15742306T patent/ES2828704T3/es active Active
- 2015-07-29 SG SG11201700785UA patent/SG11201700785UA/en unknown
- 2015-07-29 RU RU2017106602A patent/RU2729998C9/ru active
- 2015-07-29 CA CA2956529A patent/CA2956529A1/en active Pending
- 2015-07-29 KR KR1020257022052A patent/KR20250108757A/ko active Pending
- 2015-07-29 CN CN202310620718.XA patent/CN116655630B/zh active Active
- 2015-07-29 LT LTEP15742306.2T patent/LT3174875T/lt unknown
- 2015-07-29 JP JP2017505480A patent/JP6818674B2/ja active Active
- 2015-07-29 MX MX2017001507A patent/MX369467B/es active IP Right Grant
- 2015-07-29 MY MYPI2017700334A patent/MY198066A/en unknown
- 2015-07-29 CN CN202310619597.7A patent/CN116655629A/zh active Pending
- 2015-07-29 PL PL15742306T patent/PL3174875T3/pl unknown
- 2015-07-29 SI SI201531406T patent/SI3174875T1/sl unknown
- 2015-07-29 US US17/002,115 patent/USRE49575E1/en active Active
- 2015-07-29 PT PT157423062T patent/PT3174875T/pt unknown
- 2015-07-29 PE PE2017000143A patent/PE20170141A1/es unknown
- 2015-07-29 CA CA3146285A patent/CA3146285C/en active Active
- 2015-07-29 CN CN202310616268.7A patent/CN116655627A/zh active Pending
- 2015-07-29 EP EP19213735.4A patent/EP3660015A1/de not_active Withdrawn
- 2015-07-29 US US15/329,043 patent/US10059707B2/en not_active Ceased
- 2015-07-29 KR KR1020177005278A patent/KR102527893B1/ko active Active
- 2015-07-29 HR HRP20201800TT patent/HRP20201800T1/hr unknown
- 2015-07-29 BR BR112017001678-8A patent/BR112017001678B1/pt active IP Right Grant
- 2015-07-29 RS RS20201213A patent/RS60921B1/sr unknown
- 2015-07-29 EP EP15742306.2A patent/EP3174875B1/de active Active
- 2015-07-30 JO JOP/2015/0184A patent/JO3648B1/ar active
- 2015-07-30 TW TW104124689A patent/TWI684593B/zh active
- 2015-07-31 UY UY0001036251A patent/UY36251A/es not_active Application Discontinuation
- 2015-07-31 AR ARP150102475A patent/AR101403A1/es unknown
-
2017
- 2017-01-23 IL IL250239A patent/IL250239B/en active IP Right Grant
- 2017-01-31 CO CONC2017/0000886A patent/CO2017000886A2/es unknown
- 2017-01-31 CL CL2017000263A patent/CL2017000263A1/es unknown
-
2018
- 2018-08-27 US US16/114,198 patent/US10399977B2/en not_active Ceased
-
2020
- 2020-11-03 US US17/087,659 patent/USRE49860E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3648B1 (ar) | عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا | |
| JO3430B1 (ar) | مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها | |
| MY195226A (en) | Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | |
| JO3489B1 (ar) | مركبات تراي أزولوبيريميدين واستخداماتها | |
| PH12018500457A1 (en) | New phenoxymethyl derivatives | |
| JO3811B1 (ar) | مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv | |
| JOP20160185B1 (ar) | طريقة لتحضير (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2-داي ميثيل-4،1-داي هيدرو-6،1- نافثيريدين-3- كربوكساميد واسترجاع (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2- داي ميثيل-4،1- داي هيدرو-6،1- نافثيريدين-3- كربوكساميد بواسطة طرق كهروكيميائية | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| IN2013DE02977A (enExample) | ||
| TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| PH12020550905A1 (en) | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives | |
| PH12017500833A1 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| JO3610B1 (ar) | مشتقات كربوكساميد | |
| NZ742952A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| JO3487B1 (ar) | تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| MX2016008898A (es) | Antagonistas selectivos de nr2b. | |
| SG10201810361TA (en) | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication | |
| PH12014501712A1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MX350430B (es) | Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico. | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole | |
| TN2014000307A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors |